Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 557 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
北京植德（上海）律师事务所关于迈威（上海）生物科技股份有限公司2026年第二次临时股东会的法律意见书
Regulatory Filings Classification · 88% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm regarding the convening, procedures, attendees and voting results of the company’s 2026 second extraordinary general meeting. It does not present financial data or constitute an investor presentation, earnings release, or formal report such as an interim/annual report. Instead, it provides legal attestation and validation of the meeting process and vote tally, fitting the pattern of a compliance/attestation document. Under the certification rule and given it does not fall into any more specific category, this is classified as a general Regulatory Filing (RNS).
2026-06-01 Chinese
迈威生物2026年第三次临时股东会会议资料
Proxy Solicitation & Information Statement Classification · 90% confidence The document is the complete set of materials for the company’s 2026 third extraordinary shareholders’ meeting (meeting instructions, agenda, and full text of all proposals relating to director elections, remuneration schemes, audit appointments, share issue authorizations, etc.). It is sent to shareholders to inform them and solicit their votes. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-01 Chinese
迈威生物2026年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 96% confidence The document is a formal resolution announcement of the company’s second extraordinary general meeting, detailing meeting attendance, vote counts by shareholder class, and the outcome of the proposal. This exactly matches the definition of a Declaration of Voting Results & Voting Rights Announcement. It is not a presentation, earnings release, or interim report, but a vote result notice from a shareholder meeting. Therefore, the correct filing type is DVA.
2026-06-01 Chinese
迈威生物关于新增认定核心技术人员的公告
Board/Management Information Classification · 97% confidence The document is a corporate announcement by the board regarding the addition of a new core technical personnel in a senior management role. It outlines changes to the company’s management team and provides biographical details of the appointee. This fits the definition of a Board/Management Information filing (MANG) as it announces changes in senior management.
2026-05-29 Chinese
迈威生物关于公司董事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is a public announcement regarding the board of directors’ re-election (nominations of independent and non-independent directors, meeting details, candidate resumes), i.e., a change in the company’s board management. This fits the ‘‘Board/Management Information’’ category.
2026-05-29 Chinese
迈威生物独立董事提名人声明与承诺（秦正余）
Board/Management Information Classification · 88% confidence The document is a formal statement and commitment by the company’s board nominating an independent director candidate, detailing qualifications, independence declarations, and eligibility. It pertains directly to board composition and management slate announcements, fitting under the Board/Management Information category.
2026-05-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.